




RECEIVED
JUN 24 2003
TECH CENTER 1600/2900

I hereby certify that this correspondence is being deposited with the United States Postal Service first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450 Alexandria, VA 22313-1450, on June 20, 2003

DUINE INTELLECTUAL PROPERTY LAW GROUP, P.C.

By


Amelia Groth

Attorney Docket No. 407T-898010US
Client Ref. No. 2000-072-1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

#17

Plunkett
8/2/03

In re application of:

Karen Reue, et al.

Application No.: 10/028,056

Filed: December 19, 2001

For: A NOVEL GENE ASSOCIATED
WITH REGULATION OF
ADIPOSY AND INSULIN
RESPONSE

Examiner: Cynthia B. Wilder

Art Unit: 1637

INFORMATION DISCLOSURE
STATEMENT UNDER 37 CFR § 1.97 and
§ 1.98

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:


The references cited on attached form PTO-1449 are being called to the attention of the Examiner. Copies of the references are enclosed. It is respectfully requested that the cited information be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no

Karen Reue, et al.

Application No.: 10/028,056

Page 2



representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

Applicant believes that no fee is required for submission of this statement, since it is being submitted prior to the first Office Action on the merits per 37 CFR 1.97(b)(3). However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 50-0893. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,

Tom Hunter, J.D., Ph.D.
Reg. No. 38,498

RECEIVED
JUN 24 2003
TECH CENTER 1600/2900

QUINE INTELLECTUAL PROPERTY LAW GROUP, P.C.

P.O. BOX 458

Alameda, CA 94501

(510) 337-7871

Fax (510) 337-7877

TH:ag




Substitute for form 1449A-B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	Complete if Known	
	Application Number	10/028,056
	Filing Date	December 19, 2001
	First Named Inventor	Karen Reue
	Group Art Unit	1637
	Examiner Name	Cynthia B. Wilder
	Attorney Docket Number	407T-898010US
Date Submitted	June 20, 2003	

U.S. PATENT DOCUMENTS						
Examiner Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, lines, Where Relevant Passages or Relevant Figures Appeal
		Number	Kind Code (if known)			
	01	5,476,926		Speigelman et al.	12-19-1995	
	02	5,698,389		de la Brousse et al.	12-16-1997	
	03	5,723,115		Serrero	03-03-1998	
	04	5,756,467		Kagawa et al.	05-26-1998	
	05	5,776,906		Sekiya	07-07-1998	
	06	5,827,740		Pittenger	10-27-1998	
	07	5,855,917		Cook et al.	01-05-1999	
	08	5,935,810		Freidman et al.	08-10-1999	

FOREIGN PATENT DOCUMENTS								
Examiner Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		Office	Number	Kind Code (if known)				
	09	WO	93/14109 ✓	A1	W. Alton Jones Cell Science Center	07-22-1993		
	10	WO	99/29725 ✓	A1	Merck & Co., Inc.	06-17-1999		
	11	WO	99/45135 ✓	A1	Millennium Biotherapeutics, Inc.	09-10-1999		
	12	WO	99/51740 ✓	A2	Janssen Pharmaceutica N.V.	10-14-1999		
	13	WO	00/28444 ✓	A1	Intel Corporation	05-18-2000		

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	14	Ailhaud et al. (1992) "Cellular and Molecular Aspects of Adipose Tissue Development" <i>Ann. Rev. Nutr.</i> 12: 207-233 ✓	
	15	Cao and Hegele (2000) "Nuclear lamin A/C R482Q mutation in Canadian kindreds with Dunnigan-type familial partial lipodystrophy" <i>Hum. Mol. Genet.</i> 9: 109-112 ✓	
	16	Comuzzie et al. (1997) "A major quantitative trait locus determining serum leptin levels and fat mass is located on human chromosome 2" <i>Nature Genet.</i> 15: 273-275 ✓	
	17	Dörfler et al. (1993) "Lipoatrophic diabetes" <i>Clin. Investig.</i> 71: 264-269 ✓	
Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



RECEIVED
JUN 24 2003
TECH CENTER 1600/2800

Substitute for form 1449A-B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	Complete if Known	
	Application Number	10/028,056
	Filing Date	December 19, 2001
	First Named Inventor	Karen Reue
	Group Art Unit	1637
	Examiner Name	Cynthia B. Wilder
	Attorney Docket Number	407T-898010US
Date Submitted	June 20, 2003	

18	Garg (2000) "Gender Differences in the Prevalence of Metabolic Complications in Familial Partial Lipodystrophy (Dunnigan Variety)" <i>J. Clin. Endocrinol. Metab.</i> 85: 1776-1782 ✓	
19	Hager et al. (1998) "A genome-wide scan for human obesity genes reveals a major susceptibility locus on chromosome 10" <i>Nature Genet.</i> 20: 304-308 ✓	
20	Klingenspor et al. (1999) "Altered Gene Expression Pattern in the Fatty Liver Dystrophy Mouse Reveals Impaired Insulin-mediated Cytoskeleton Dynamics" <i>J. Biol. Chem.</i> 274: 23078-23084 ✓	
21	Langner et al. (1989) "The Fatty Liver Dystrophy (<i>fld</i>) Mutation" <i>J. Biol. Chem.</i> 264: 7994-8003 ✓	
22	Langner et al. (1991) "Characterization of the Peripheral Neuropathy in Neonatal and Adult Mice That Are Homozygous for the Fatty Liver Dystrophy (<i>fld</i>) Mutation" <i>J. Biol. Chem.</i> 266: 11955-11964	
23	Péterfy et al. (1999) "Genetic, Physical, and Transcript Map of the <i>fld</i> Region on Mouse Chromosome 12" <i>Genomics</i> 62: 436-444 ✓	
24	Rehnmark et al. (1998) "The fatty liver dystrophy mutant mouse: microvesicular steatosis associated with altered expression levels of peroxisome proliferator-regulated proteins" <i>J. Lipid Res.</i> 39: 2209-2217 ✓	
25	Rotimi et al. (1999) "The Quantitative Trait Locus on Chromosome 2 for Serum Leptin Levels Is Confirmed in African-Americans" <i>Diabetes</i> 48: 643-644 ✓	
26	Seip and Trygstad (1996) "Generalized lipodystrophy, congenital and acquired (lipoatrophy)" <i>Acta Paediatr. Scand. Suppl.</i> 413: 2-28 ✓	
27	Senior and Gellis (1964) "The Syndromes of Total Lipodystrophy and of Partial Lipodystrophy" <i>Pediatrics</i> 33: 593-612 ✓	
28	Shackleton et al. (2000) "LMNA, encoding lamin A/C, is mutated in partial lipodystrophy" <i>Nature Genet.</i> 24: 153-156 ✓	
29	Shimomura et al. (1998) "Insulin resistance and diabetes mellitus in transgenic mice expressing nuclear SREBP-1c in adipose tissue: model for congenital generalized lipodystrophy" <i>Genes. Dev.</i> 12: 3182-3194 ✓	
30	Shimomura et al. (1999) "Congenital generalized lipodystrophy (CGL) is a rare autosomal recessive disorder characterized by a paucity of adipose (fat) tissue which is evident at birth and..." <i>Nature</i> 401: 73-76 ✓	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.